A ctDNA-guided approach can help identify when patients with HR-positive advanced breast cancer are developing an ESR1 ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

At the annual conference of the European Society of Human Genetics in Milan, biologist Dr. Edwige Kasper from the University ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...

Jacifusen was generally well tolerated and reversed disease progression in some people with ALS caused by mutations in the ...

DataM Intelligence | competitive Intelligence Gene therapies, exon-skipping drugs and next-gen steroids are reshaping Duchenne muscular dys ...

Approximately 70% of breast cancers are HR-positive/HER2 negative. While activating ESR1 mutations are rare at the time of ...

MSD’s investigational KRAS G12C inhibitor has shown signs of anti-tumour activity when used both alone and in combination ...

CHICAGO >> Treating breast cancer patients with AstraZeneca’s experimental pill camizestrant at the first sign of resistance ...

As newborn screening and rapid DNA sequencing become routine, we are poised to catch and treat inherited diseases at their ...

A new review sheds light on the complex molecular mechanisms behind Angelman syndrome (AS), a rare neurogenetic disorder, and ...